Zacks Analyst Blog Highlights: Myriad Genetics, BioMarin Pharmaceuticals, Abbott Laboratories, AstraZeneca and Sanofi-Aventis


CHICAGO, April 8, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Myriad Genetics (Nasdaq: MYGN), BioMarin Pharmaceuticals (Nasdaq: BMRN), Abbott Laboratories (NYSE: ABT), AstraZeneca (NYSE: AZN) and Sanofi-Aventis (NYSE: SNY).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:

Here are highlights from Friday's Analyst Blog: 

Myriad-BioMarin in Testing Deal

Myriad Genetics (Nasdaq: MYGN) has entered into an agreement with BioMarin Pharmaceuticals (Nasdaq: BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter's phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers.

Bracanalysisis Myriad's flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman's risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians.

Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish Bracanalysis as a companion diagnostic for PARP inhibitors, Myriad has got into agreements with Abbott Laboratories (NYSE: ABT) and AstraZeneca (NYSE: AZN). PARP inhibitor is a promising oncology drug candidate under development and these drugs could be on the market in the 2012-2013 timeframe.

At present, Bracanalysis targets about a third of newly diagnosed and recurrent cases of breast cancer. However, Myriad believes that any woman being considered for a PARP inhibitor would be tested for the presence of BRCA mutations to check if she would respond to the drug. As a result, the targeted population would increase to include all women who would be appropriate for chemotherapy, bloating up the oncology market.

In January 2011, Sanofi-Aventis (NYSE: SNY) announced disappointing results for iniparib from a phase III study conducted with 519 women suffering from metastatic triple-negative breast cancer (mTNBC). Results showed that iniparib failed to prolong overall survival and progression-free survival in these patients. While this comes as a setback for PARP inhibitors, AstraZeneca is progressing with a phase III clinical study in ovarian cancer where the enrollment criteria will be based on BRCA status.

We are currently Neutral on Myriad, which also corresponds to the Zacks #3 Rank (Hold) in the short term.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks 

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time!Register for your free subscription to Profit from the Pros

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
YouTube Channel: http://www.youtube.com/user/ZacksInvestmentNews

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.